Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 4 min read
Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability.
| 5 min read
Rodrigo Cristofoletti discusses how cerebral organoids, advanced imaging, and quantitative modeling are helping researchers better understand brain development, disease, and drug discovery.
| 6 min read
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
| 5 min read
New conjugation chemistries are giving developers greater control over targeting, stability, and payload release.
| 6 min read
As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable.
| 6 min read
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
| 4 min read
As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets.
| 5 min read
By combining genomics, brain imaging, and digital biomarkers, the MAP-D initiative aims to redefine depression through biology rather than symptoms alone.
| 3 min read
A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics.
| 6 min read
Researchers are moving beyond the male default as evidence reveals how sex influences disease, drug response, and clinical outcomes.
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 3 min read
Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
